The Current Status of Adjuvant Chemotherapy for Colorectal Cancer in Japan: A Paradigm Shift from Oral Fluoropyridine Single Therapy to the Oxaliplatin Regimen.

Cancers (Basel) · 2025 · PMC11817369 · PMID 39941884

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Overall, no significant difference was observed for Stage II patients; however, when limited to high-risk Stage II patients, a favorable trend was observed in the FOLFOX group (5-year DFS: FOLFOX group—82.3%; LV5FU2 group—74.6%; HR = 0.72).

also in 805 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.